

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine

Quixabeira DCA^{1,2}, Jirovec E¹, Pakola S¹, Havunen R^{1,2}, Basnet S¹, Santos JM^{1,2}, Kudling TV¹, Clubb JHA^{1,2}, Haybout L¹, Arias V¹, Grönberg-Vähä-Koskela S^{1,3}, Cervera-Carrascon V^{1,2}, Pasanen A⁴, Anttila M⁵, Tapper J⁶, Kanerva A⁶, and Hemminki A^{1,2,3*}

Supplements

Supplementary Table 1- Flow cytometry panel				
Antigen	Fluochrome	Clone	Catalogue Number	Provider
CD3	AF700	SK7	344822	Biolegend
CD4	BV570	RPA-T4	300534	Biolegend
CD8	BV510	RPA-T8	563256	BD
PD-1	APC-Cy7	EH12.2H7	329922	Biolegend
CD25	BV711	M-A251	356138	Biolegend
FoxP3	PE-Dazzle	206D	320126	Biolegend
GrzmB	PE	GB11	561142	BD
EpCam	PE-Dazzle	9C4	324232	Biolegend
CD56	BV510	HCD56	318340	Biolegend

Supplementary Table 1. List of Antibodies and fluorochromes used for the immune cells studies.

Supplementary Table 2- IHC antibody panel		
Antibody	Dilution used	Provider
CD4 (104R-16)	1:100	Cell Marque
CD8 (NCL-CD8-4B11)	1:50	N-C
CD56 (156R-96)	1:500	Cell Marque
PD-L1 (741-4860)	Ready to use	Roche

Supplementary Table 2. List of antibodies used for the immunohistochemistry staining of OvCa slides.